Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
- Conditions
- Non Small Cell Lung CancerEpidermal Growth Factor Receptor Gene MutationStage III Lung CancerStage IV Lung Cancer
- Interventions
- First Posted Date
- 2024-08-05
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 538
- Registration Number
- NCT06538038
- Locations
- 🇺🇸
Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States
🇺🇸Metro MN, Saint Louis Park, Minnesota, United States
🇺🇸Regions Hospital, Saint Paul, Minnesota, United States
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
- Conditions
- Pleural MesotheliomaMesotheliomaMalignant Pleural Mesothelioma
- Interventions
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 214
- Registration Number
- NCT04334759
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸The Ohio State University, Columbus, Ohio, United States
Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 181
- Registration Number
- NCT03836209
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸University of Rochester Medical Center, Rochester, New York, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 33
- Registration Number
- NCT03834688
- Locations
- 🇺🇸
Carle Cancer Center, Urbana, Illinois, United States
🇺🇸Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 43
- Registration Number
- NCT03532451
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
- First Posted Date
- 2017-10-26
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 43
- Registration Number
- NCT03323151
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸University of Kansas, Overland Park, Kansas, United States
🇺🇸West Virginia University, Morgantown, West Virginia, United States
Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy
- Conditions
- Follicular LymphomaNon-Hodgkin's Lymphoma FollicularNon-Hodgkin's Lymphoma, Adult High Grade
- Interventions
- Drug: Induction VenetoclaxDrug: Maintenance Venetoclax
- First Posted Date
- 2017-04-13
- Last Posted Date
- 2024-01-09
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 56
- Registration Number
- NCT03113422
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Fox Chase, Philadelphia, Pennsylvania, United States
🇺🇸Gunderson Health System Cancer Center, La Crosse, Wisconsin, United States
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 55
- Registration Number
- NCT02899195
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung
- Conditions
- Squamous Cell Carcinoma of the Lung
- First Posted Date
- 2016-03-21
- Last Posted Date
- 2019-07-16
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 13
- Registration Number
- NCT02713828
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸West Virginia University, Morgantown, West Virginia, United States
Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- PrECOG, LLC.
- Target Recruit Count
- 74
- Registration Number
- NCT02181634
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Advocate Christ Medical Center, Oak Lawn, Illinois, United States